These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 39240544)

  • 1. The Latest Research About Paxlovid: Effectiveness, Access, and Possible Long COVID Benefits.
    Rubin R
    JAMA; 2024 Oct; 332(13):1040-1042. PubMed ID: 39240544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paxlovid for treatment of COVID-19.
    Med Lett Drugs Ther; 2022 Jan; 64(1642):9-10. PubMed ID: 35134040
    [No Abstract]   [Full Text] [Related]  

  • 3. Nirmatrelvir/Ritonavir (Paxlovid) Use Among Individuals at Risk of Severe COVID-19: An Analysis of the National COVID Cohort Collaborative (N3C).
    Xiao X; Alexander GC; Mehta HB
    Pharmacoepidemiol Drug Saf; 2024 Aug; 33(8):e5869. PubMed ID: 39099263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of Potential Drug Interactions With Direct-Acting Antivirals for COVID-19 Among Hospitalized Patients.
    Mozaffari E; Chandak A; Ustianowski A; Rivera CG; Ahuja N; Jiang H; Berry M; Okulicz JF; Amin AN
    Clin Ther; 2024 Oct; 46(10):778-784. PubMed ID: 39244489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of COVID-19 in high-risk outpatients.
    Med Lett Drugs Ther; 2022 Feb; 64(1643):e1. PubMed ID: 35134051
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of the therapeutic effect of Paxlovid and Azvudine in the treatment of COVID-19: A retrospective study.
    Yang W; Zhang W; Zhou J; Ma X; Wang C; Zhao M; Yu K
    J Infect Public Health; 2024 Dec; 17(12):102583. PubMed ID: 39500259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From Positive to Negative to Positive Again-The Mystery of Why COVID-19 Rebounds in Some Patients Who Take Paxlovid.
    Rubin R
    JAMA; 2022 Jun; 327(24):2380-2382. PubMed ID: 35675094
    [No Abstract]   [Full Text] [Related]  

  • 8. A National Strategy for COVID-19 Medical Countermeasures: Vaccines and Therapeutics.
    Borio LL; Bright RA; Emanuel EJ
    JAMA; 2022 Jan; 327(3):215-216. PubMed ID: 34989782
    [No Abstract]   [Full Text] [Related]  

  • 9. Paxlovid Is Effective but Underused-Here's What the Latest Research Says About Rebound and More.
    Rubin R
    JAMA; 2024 Feb; 331(7):548-551. PubMed ID: 38294771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nirmatrelvir-Ritonavir and Viral Load Rebound in Covid-19.
    Anderson AS; Caubel P; Rusnak JM;
    N Engl J Med; 2022 Sep; 387(11):1047-1049. PubMed ID: 36069818
    [No Abstract]   [Full Text] [Related]  

  • 11. Azvudine versus Paxlovid in COVID-19: A systematic review and meta-analysis.
    Amani B; Amani B
    Rev Med Virol; 2024 Jul; 34(4):e2551. PubMed ID: 38849982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nirmatrelvir-ritonavir for COVID-19.
    McDonald EG; Lee TC
    CMAJ; 2022 Feb; 194(6):E218. PubMed ID: 35115376
    [No Abstract]   [Full Text] [Related]  

  • 13. Audio Interview: A New Antiviral against Covid-19.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2022 Feb; 386(7):e25. PubMed ID: 35172062
    [No Abstract]   [Full Text] [Related]  

  • 14. Supratherapeutic INR During Treatment With Nirmatrelvir/Ritonavir and Warfarin and Acute Illness With COVID-19: A Case Report.
    Dowd-Green C; Brown D; Wilson A; Streiff M
    J Pharm Pract; 2024 Dec; 37(6):1414-1418. PubMed ID: 38803049
    [No Abstract]   [Full Text] [Related]  

  • 15. Rebound of SARS-CoV-2 Infection after Nirmatrelvir-Ritonavir Treatment.
    Charness ME; Gupta K; Stack G; Strymish J; Adams E; Lindy DC; Mohri H; Ho DD
    N Engl J Med; 2022 Sep; 387(11):1045-1047. PubMed ID: 36069968
    [No Abstract]   [Full Text] [Related]  

  • 16. Effectiveness of Nirmatrelvir-Ritonavir for the Prevention of COVID-19-Related Hospitalization and Mortality: A Systematic Literature Review.
    Cha-Silva AS; Gavaghan MB; Bergroth T; Alexander-Parrish R; Yang J; Draica F; Patel J; Garner DA; Stanford RH; Meier G; McLaughlin JM; Nguyen JL
    Am J Ther; 2024 May-Jun 01; 31(3):e246-e257. PubMed ID: 38691664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single-centre study.
    Gentile I; Viceconte G; Cuccurullo F; Pietroluongo D; D'Agostino A; Silvitelli M; Mercinelli S; Scotto R; Grimaldi F; Palmieri S; Gravetti A; Trastulli F; Moccia M; Buonomo AR
    Ann Med; 2025 Dec; 57(1):2439541. PubMed ID: 39661366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Molnupiravir or nirmatrelvir-ritonavir reduce the likelihood of hospitalization and mortality in immunocompromised patients with Covid-19.].
    Kurotschka PK; Ebell MH; Serafini A
    Recenti Prog Med; 2024 Sep; 115(9):399. PubMed ID: 39269352
    [No Abstract]   [Full Text] [Related]  

  • 19. Effectiveness of the antiviral medications azvudine and nirmatrelvir-ritonavir in treating COVID-19 in patients with hematological malignancies.
    Zeng Z; Li F; Zhong M; Zhu L; Chen W; Wang X
    Clinics (Sao Paulo); 2024; 79():100406. PubMed ID: 39059144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation study for assessing COVID-19 pneumonia treatments.
    Lin K; Zhou B; Wu Y; Wang Z; Li S; Li Y; Li F; Xue Y; Liu Z; Liao J
    Sci Rep; 2024 Nov; 14(1):29195. PubMed ID: 39587139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.